Top

Published in:

01-04-2014 | Molecular Imaging (G Strijkers)

Molecular Imaging of Macrophage Enzyme Activity in Cardiac Inflammation

Authors: Muhammad Ali, Benjamin Pulli, John W. Chen

Published in: Current Cardiovascular Imaging Reports | Issue 4/2014

Abstract

Molecular imaging is highly advantageous as various insidious inflammatory events can be imaged in a serial and quantitative fashion. Combined with the conventional imaging modalities like computed tomography (CT), magnetic resonance (MR), and nuclear imaging, it helps us resolve the extent of ongoing pathology, quantify inflammation, and predict outcome. Macrophages are increasingly gaining importance as an imaging biomarker in inflammatory cardiovascular diseases. Macrophages, recruited to the site of injury, internalize necrotic or foreign material. Along with phagocytosis, activated macrophages release proteolytic enzymes like matrix metalloproteinases (MMPs) and cathepsins into the extracellular environment. Proinflammatory monocytes and macrophages also induce tissue oxidative damage through the inflammatory enzyme myeloperoxidase (MPO). In this review we will highlight recent advances in molecular macrophage imaging. Particular stress will be given to macrophage functional and enzymatic activity imaging, which targets phagocytosis, proteolysis, and myeloperoxidase activity imaging.

Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–60S.

Majmudar MD, Nahrendorf M. Cardiovascular molecular imaging: the road ahead. J Nucl Med. 2012;53(5):673–6.

Nahrendorf M, Sosnovik DE, French BA, Swirski FK, Bengel F, Sadeghi MM, et al. Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging. 2009;2(1):56–70.PubMedCentralPubMedCrossRef

Sinusas AJ, Bengel F, Nahrendorf M, Epstein FH, Wu JC, Villanueva FS, et al. Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging. 2008;1(3):244–56.PubMedCrossRef

Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037–47.PubMedCentralPubMedCrossRef

Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487(7407):325–9.PubMedCentralPubMedCrossRef

Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166–72.PubMedCentralPubMedCrossRef

Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation. 2005;80(12):1641–7.PubMedCrossRef

Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol. 2010;10(6):453–60.PubMedCentralPubMedCrossRef

10.

Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res. 2012;111(2):231–44.PubMedCentralPubMedCrossRef

11.

Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging. 2009;2(10):1213–22.PubMedCentralPubMedCrossRef

12.

Choi KS, Kim SH, Cai QY, Kim SY, Kim HO, Lee HJ, et al. Inflammation-specific T1 imaging using anti-intercellular adhesion molecule 1 antibody-conjugated gadolinium diethylenetriaminepentaacetic acid. Mol Imaging. 2007;6(2):75–84.PubMed

13.

Kitagawa T, Kosuge H, Chang E, James ML, Yamamoto T, Shen B, et al. Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography. Circ Cardiovasc Imaging. 2013;6(6):950–6.PubMedCrossRef

14.

Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593–623.PubMedCrossRef

15.

Sosnovik DE, Nahrendorf M, Weissleder R. Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol. 2008;103(2):122–30.PubMedCentralPubMedCrossRef

16.

Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol. 2002;9 Suppl 2:S304–6.PubMedCrossRef

17.

Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc. 2004;126(50):16316–7.PubMedCrossRef

18.

Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med. 2006;56(3):601–10.PubMedCrossRef

19.

Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011;44(10):842–52.PubMedCentralPubMedCrossRef

20.

Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 2004;51(3):480–6.PubMedCrossRef

21.

Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23(11):1418–23.PubMedCrossRef

22.

Segers FM, den Adel B, Bot I, van der Graaf LM, van der Veer EP, Gonzalez W, et al. Scavenger receptor-AI-targeted iron oxide nanoparticles for in vivo MRI detection of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2013;33(8):1812–9.PubMedCrossRef

23.

Simon G, Bauer J, Saborovski O, Fu Y, Corot C, Wendland M, et al. T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol. 2006;16(3):738–45.PubMedCrossRef

24.

Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol Imaging. 2006;5(2):85–92.PubMed

25.

Sosnovik DE, Nahrendorf M, Deliolanis N, Novikov M, Aikawa E, Josephson L, et al. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation. 2007;115(11):1384–91.PubMedCrossRef

26.

Trivedi RA, Mallawarachi C, U-King-Im JM, Graves MJ, Horsley J, Goddard MJ, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26(7):1601–6.PubMedCrossRef

27.••

Yilmaz A, Dengler MA, van der Kuip H, Yildiz H, Rösch S, Klumpp S, et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur Heart J. 2013;34(6):462–75. In this clinical trial, authors compared ferumoxytol (Feraheme™, FH), an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO), to conventional gadolinium based agents in patients with acute myocardial infarction. T2* contrast was recognized not only in the infarct core and peri-infarct tissue but also in the remote myocardium suggesting macrophage infiltration and possible remote tissue remodeling.PubMedCrossRef

28.

Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5(5):559–65.PubMedCrossRef

29.•

Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53(22):2039–50. In this clinical trial, high and low dose atorvastatin treatment response was followed in patients with carotid atherosclerosis. Only high dose statin demonstrated measurable changes in carotid plaque inflammation as defined by the USPIO-enhanced MRI, within first 3 months of therapy. This study signifies USPIO based macrophage imaging as a useful tool for assessing therapeutic response.PubMedCrossRef

30.

Olzinski AR, Turner GH, Bernard RE, Karr H, Cornejo CA, Aravindhan K, et al. Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment. Arterioscler Thromb Vasc Biol. 2010;30(2):253–9.PubMedCrossRef

31.

Sigovan M, Kaye E, Lancelot E, Corot C, Provost N, Majd Z, et al. Anti-inflammatory drug evaluation in ApoE−/− mice by ultrasmall superparamagnetic iron oxide–enhanced magnetic resonance imaging. Investig Radiol. 2012;47(9):546–52. doi:10.1097/RLI.0b013e3182631e68.CrossRef

32.•

Millon A, Dickson SD, Klink A, Izquierdo-Garcia D, Bini J, Lancelot E, et al. Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner. Atherosclerosis. 2013;228(2):339–45. By using a combined PET/MRI scanner, authors compared (18)F-FDG PET and USPIO based MRI to assess plaque inflammation changes induced by atorvastatin and dietary change in a rabbit model of atherosclerosis. There was a decrease in the standard uptake value of (18)F-FDG after six months of treatment. Similar response was also measured in R2* with the help of USPIO imaging.PubMedCrossRef

33.

Wu YL, Ye Q, Sato K, Foley LM, Hitchens TK, Ho C. Noninvasive evaluation of cardiac allograft rejection by cellular and functional cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2(6):731–41.PubMedCentralPubMedCrossRef

34.

Yang CY, Tai MF, Lin CP, Lu CW, Wang JL, Hsiao JK, et al. Mechanism of cellular uptake and impact of ferucarbotran on macrophage physiology. PLoS One. 2011;6(9):e25524.PubMedCentralPubMedCrossRef

35.

Naresh NK, Xu Y, Klibanov AL, Vandsburger MH, Meyer CH, Leor J, et al. Monocyte and/or macrophage infiltration of heart after myocardial infarction: MR imaging by using T1-shortening liposomes. Radiology. 2012;264(2):428–35.PubMedCentralPubMedCrossRef

36.

Dellinger A, Olson J, Link K, Vance S, Sandros MG, Yang J, et al. Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013;15:7.PubMedCentralPubMedCrossRef

37.

Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D, et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging. 2009;2(5):637–47.PubMedCentralPubMedCrossRef

38.

Flögel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008;118(2):140–8.PubMedCentralPubMedCrossRef

39.

Flögel U, Su S, Kreideweiß I, Ding Z, Galbarz L, Fu J, et al. Noninvasive detection of graft rejection by in vivo 19F MRI in the early stage. Am J Transplant. 2011;11(2):235–44.PubMedCrossRef

40.

Panizzi P, Swirski FK, Figueiredo JL, Waterman P, Sosnovik DE, Aikawa E, et al. Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol. 2010;55(15):1629–38.PubMedCentralPubMedCrossRef

41.•

Vinegoni C, Botnaru I, Aikawa E, Calfon MA, Iwamoto Y, Folco EJ, et al. Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques. Sci Transl Med. 2011;3(84):84ra45. This study explains that the indocyanin green is taken up by lipid rich foam cells and can be imaged with intravenous near infrared detection catheter in rabbit vessels. Being widely available and FDA approved, indocyanin has a promise for clinical macrophage imaging in human coronary disease as well.PubMedCentralPubMed

42.

Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y. What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med. 2012;53(1):55–8.PubMedCrossRef

43.

Truijman MT, Kwee RM, van Hoof RH, Hermeling E, van Oostenbrugge RJ, Mess WH, et al. Combined 18F-FDG PET-CT and DCE-MRI to assess inflammation and microvascularization in atherosclerotic plaques. Stroke. 2013;44(12):3568–70.PubMedCrossRef

44.

Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50(9):892–6.PubMedCrossRef

45.

Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–59.PubMedCrossRef

46.••

Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–17. In this similar clinical trial, PET/CT imaging with (18)F-FDG was used to assess high and low dose atorvastatin treatment response in patients with carotid atherosclerosis. Again, high dose treatment produced significant reductions in FDG uptake that may represent changes in atherosclerotic plaque inflammation. This study signifies (18)F-FDG based macrophage imaging as an important tool for therapeutic response follow up.PubMedCrossRef

47.

Peterson LR, Gropler RJ. Radionuclide imaging of myocardial metabolism. Circ Cardiovasc Imaging. 2010;3(2):211–22.PubMedCrossRef

48.

Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol. 2011;58(6):603–14.PubMedCrossRef

49.

Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117(3):379–87.PubMedCentralPubMedCrossRef

50.

Majmudar MD, Yoo J, Keliher EJ, Truelove JJ, Iwamoto Y, Sena B, et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res. 2013;112(5):755–61.PubMedCentralPubMedCrossRef

51.

Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins CS, Gerszten RE, et al. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol. 2011;31(4):750–7.PubMedCentralPubMedCrossRef

52.•

Ueno T, Dutta P, Keliher E, Leuschner F, Majmudar M, Marinelli B, et al. Nanoparticle PET-CT detects rejection and immunomodulation in cardiac allografts. Circ Cardiovasc Imaging. 2013;6(4):568–73. Trimodality contrats nanoagents have been used in the past as well. In this recent study, Ueno et al. reported use of a macrophage avid trimodality PET and magnetofluorescent nanoparticle in mouse model of cardiac transplant rejection. Additionally, immunosuppressive response with angiotensin converting enzyme inhibitor was also quantified with this novel imaging agent which resulted in better allograft survival.PubMedCentralPubMedCrossRef

53.

Keliher EJ, Yoo J, Nahrendorf M, Lewis JS, Marinelli B, Newton A, et al. 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjug Chem. 2011;22(12):2383–9.PubMedCentralPubMedCrossRef

54.

Settles M, Etzrodt M, Kosanke K, Schiemann M, Zimmermann A, Meier R, et al. Different capacity of monocyte subsets to phagocytose iron-oxide nanoparticles. PLoS One. 2011;6(10):e25197.PubMedCentralPubMedCrossRef

55.

Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77(5):863–8.PubMedCrossRef

56.

Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007;21(12):3029–41.PubMedCrossRef

57.

Hermann S, Starsichova A, Waschkau B, Kuhlmann M, Wenning C, Schober O, et al. Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability? J Nucl Cardiol. 2012;19(3):609–17.PubMedCrossRef

58.

Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med. 2011;52(11):1795–802.PubMedCentralPubMedCrossRef

59.

Razavian M, Zhang J, Nie L, Tavakoli S, Razavian N, Dobrucki LW, et al. Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nucl Med. 2010;51(7):1107–15.PubMedCentralPubMedCrossRef

60.

Sahul ZH, Mukherjee R, Song J, McAteer J, Stroud RE, Dione DP, et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011;4(4):381–91.PubMedCentralPubMedCrossRef

61.

Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007;115(17):2292–8.PubMedCrossRef

62.

Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol. 2009;29(10):1444–51.PubMedCentralPubMedCrossRef

63.

Sheth RA, Maricevich M, Mahmood U. In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis. 2010;212(1):181–7.PubMedCentralPubMedCrossRef

64.

Nahrendorf M, Sosnovik DE, Waterman P, Swirski FK, Pande AN, Aikawa E, et al. Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res. 2007;100(8):1218–25.PubMedCrossRef

65.

Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118(18):1802–9.PubMedCentralPubMedCrossRef

66.

Jaffer FA, Calfon MA, Rosenthal A, Mallas G, Razansky RN, Mauskapf A, et al. Two-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury. J Am Coll Cardiol. 2011;57(25):2516–26.PubMedCentralPubMedCrossRef

67.••

Yoo H, Kim JW, Shishkov M, Namati E, Morse T, Shubochkin R, et al. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011;17(12):1680–4. This study combines macrophage protease activity with high resolution structural imaging (optical frequency domain imaging) as imaged in rabbit vessels comparable in size to human coronary arteries. Both technologies were mounted on a same catheter and provided a powerful tool to image in vivo plaque inflammation superimposed on detailed vessel anatomy.PubMedCentralPubMedCrossRef

68.

Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009;2(11):1035–46.PubMedCrossRef

69.

van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal. 2009;11(11):2899–937.PubMedCrossRef

70.

Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25(6):1102–11.PubMedCrossRef

71.

Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110(9):1134–9.PubMedCentralPubMedCrossRef

72.

Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114(4):529–41.PubMedCentralPubMedCrossRef

73.

Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101(35):13032–7.PubMedCentralPubMedCrossRef

74.

Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197(5):615–24.PubMedCentralPubMedCrossRef

75.

Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55(8):1462–70.PubMedCrossRef

76.

Zhang R, Brennan M, Fu X, et al. ASsociation between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286(17):2136–42.PubMedCrossRef

77.

Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108(12):1440–5.PubMedCrossRef

78.

Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349(17):1595–604.PubMedCrossRef

79.

Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50(2):159–65.PubMedCrossRef

80.

Chen JW, Pham W, Weissleder R, Bogdanov Jr A. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn Reson Med. 2004;52(5):1021–8.PubMedCrossRef

81.

Chen JW, Querol Sans M, Bogdanov Jr A, Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology. 2006;240(2):473–81.PubMedCrossRef

82.

Pulli B, Ali M, Forghani R, Schob S, Hsieh KL, Wojtkiewicz G, et al. Measuring myeloperoxidase activity in biological samples. PLoS One. 2013;8(7):e67976.PubMedCentralPubMedCrossRef

83.

Rodriguez E, Nilges M, Weissleder R, Chen JW. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc. 2010;132(1):168–77.PubMedCentralPubMedCrossRef

84.

Ronald JA, Chen JW, Chen Y, Hamilton AM, Rodriguez E, Reynolds F, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation. 2009;120(7):592–9.PubMedCentralPubMedCrossRef

85.

Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo JL, Aikawa E, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation. 2008;117(9):1153–60.PubMedCentralPubMedCrossRef

86.

Breckwoldt MO, Chen JW, Stangenberg L, Aikawa E, Rodriguez E, Qiu S, et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A. 2008;105(47):18584–9.PubMedCentralPubMedCrossRef

87.••

Swirski FK, Wildgruber M, Ueno T, Figueiredo JL, Panizzi P, Iwamoto Y, et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J Clin Invest. 2010;120(7):2627–34. For cardiac transplant rejection, serial biopsy is the current standard, which is invasive and prone to sampling error. In this study, Swirski et al. reported use of a gadolinium based agent specific for enzyme myeloperoxidase (MPO-Gd), which can be used as an imaging biomarker for cardiac rejection. Additionally, MPO-Gd was also able to follow immunosuppressive response non-invasively.PubMedCentralPubMedCrossRef

88.

Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain. 2008;131(Pt 4):1123–33.PubMedCrossRef

89.

Forghani R, Wojtkiewicz GR, Zhang Y, Seeburg D, Bautz BR, Pulli B, et al. Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target. Radiology. 2012;263(2):451–60.PubMedCentralPubMedCrossRef

90.

Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl. 2003;84:S172–6.PubMedCrossRef

91.

Nikpoor B, Turecki G, Fournier C, Théroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142(2):336–9.PubMedCrossRef

92.

Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis the good, the bad, and the ugly. Circ Res. 2002;90(3):251–62.PubMed

93.

Nahrendorf M, Swirski FK. Monocyte and macrophage heterogeneity in the heart. Circ Res. 2013;112(12):1624–33.PubMedCrossRef

Title: Molecular Imaging of Macrophage Enzyme Activity in Cardiac Inflammation
Authors: Muhammad Ali
Benjamin Pulli
John W. Chen
Publication date: 01-04-2014
Publisher: Springer US
Published in: Current Cardiovascular Imaging Reports / Issue 4/2014
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-014-9258-0

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular Imaging of Macrophage Enzyme Activity in Cardiac Inflammation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Contrast-Enhanced T1-Mapping MRI for the Assessment of Myocardial Fibrosis

Animal Models of Tissue Characterization of Area at Risk, Edema and Fibrosis

Measuring Wall Shear Stress Using Velocity-Encoded MRI

Novel Approaches to Myocardial Perfusion: 3D First-Pass CMR Perfusion Imaging and Oxygenation-Sensitive CMR

T1 Mapping in Ischemic Heart Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page